Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against epidermal growth-factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)/c-ros oncogen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Bylicki, Olivier, Guisier, Florian, Monnet, Isabelle, Doubre, Hélène, Gervais, Radj, Janicot, Henri, Perol, Maurice, Fournel, Pierre, Lamy, Régine, Auliac, Jean-Bernard, Chouaid, Christos
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2020
Assuntos:
5700
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7220079/
https://ncbi.nlm.nih.gov/pubmed/32011450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000018726
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados